Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).
PDC*line Pharma
News
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to
New Article Featuring Our CEO Eric Halioua Published in BioProcess International
We are thrilled to announce that BioProcess International, a leading global platform for the bioprocessing industry, has published a new article featuring an interview with our CEO, Eric Halioua. In this piece, Eric shares the remarkable journey of
PDC*line Pharma’s Phase I/II Trial Primary Clinical Results Selected for Mini Oral Presentation at ESMO-IO 2024
PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the European Society for Medical Oncology - Immuno-Oncology Congress 2024
PDC*line Pharma has been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI)
We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg from October 9 to 11, 2024!
The presentation
PDC*LINE PHARMA HAS BEEN SELECTED FOR AN ORAL PRESENTATION AT THE ANNUAL MEETING OF KOREAN CANCER ASSOCIATION
We are delighted to announce that we have been selected for an oral presentation at the International Session of the 50th Annual Meeting of Korean Cancer Association (KCA 2024)! PDC*line Pharma received the KCA International Abstract Award this year